The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: Results of an international survey
Abstract
Standardization of terminology used to describe the pattern and course of MS is essential for mutual understanding between clinicians and investigators. It is particularly important in design of, and recruitment for, clinical trials statistically powered for expected outcomes for given patient populations with narrowly defined entry criteria. For agents that prove safe and effective for MS, knowledge of the patient populations in definitive clinical trials assists clinicians in determining who may ultimately benefit from use of the medication. An international survey of clinicians involved with MS revealed areas of consensus about some terms classically used to describe types of the disease and other areas for which there was lack of consensus. In this report, we provide a summary of the survey results and propose standardized definitions for the most common clinical courses of patients with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Major differences in the dynamics of primary and secondary progressive multiple sclerosis
Thompson, A. J., Kermode, A. G., Wicks, D., MacManus, D. G., Kendall, B. E., Kingsley, D. P. E., & McDonald, W. I. (1991) · Annals of Neurology · doi:10.1002/ana.410290111 · Cited by 486
SERIAL GADOLINIUM ENHANCED MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS
MILLER, D. H., RUDGE, P., JOHNSON, G., KENDALL, B. E., MACMANUS, D. G., MOSELEY, I. F., BARNES, D., & MCDONALD, W. I. (1988) · Brain · doi:10.1093/brain/111.4.927 · Cited by 407
Autosomal dominant cerebellar phenotypes: The genotype has settled the issue
Rosenberg, R. N. (1995) · Neurology · doi:10.1212/wnl.45.1.1 · Cited by 402
Megadose corticosteroids in multiple sclerosis
Kupersmith, M. J., Kaufman, D., Paty, D. W., Ebers, G., McFarland, H., Johnson, K., Reingold, S., & Whitaker, J. (1994) · Neurology · doi:10.1212/wnl.44.1.1 · Cited by 386
Self-citationEDMUS, a European database for multiple sclerosis.
Confavreux, C., Compston, D. A., Hommes, O. R., McDonald, W. I., & Thompson, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.8.671 · Cited by 313
NAESER, M. A., PALUMBO, C. L., HELM-ESTABROOKS, N., STIASSNY-EDER, D., & ALBERT, M. L. (1989) · Brain · doi:10.1093/brain/112.1.1 · Cited by 298
Willoughby, E. W., Grochowski, E., Li, D. K. B., Oger, J., Kastrukoff, L. F., & Paty, D. W. (1989) · Annals of Neurology · doi:10.1002/ana.410250107 · Cited by 254
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis
Whitaker, J., McFarland, H., Rudge, P., & Reingold, S. (1995) · Multiple Sclerosis Journal · doi:10.1177/135245859500100107 · Cited by 236
Self-citationDuchenne muscular dystrophy: High frequency of deletions
Bartlett, R. J., Pericak-Vance, M. A., Koh, J., Yamaoka, L. H., Chen, J. C., Hung, W. Y., Speer, M. C., Wapenaar, M. C., B. Van Ommen, G. J., Bakker, E., et al. (1988) · Neurology · doi:10.1212/wnl.38.1.1 · Cited by 196
Cited by
Items 201–217 of 217
El-Maghraby, T. A., Shalby, N. M., Al-Tawdy, M. H., & Salem, S. S. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/103615 · Cited by 35
Lin, J.-P., Brake, A., Donadieu, M., Lee, A., Smith, G., Hu, K., Nair, G., Kawaguchi, R., Sati, P., Geschwind, D. H., et al. (2025) · Science · doi:10.1126/science.adp6325 · Cited by 35
Plasma chitotriosidase activity in multiple sclerosis
Comabella, M., Domínguez, C., Rio, J., Martín-Gallán, P., Vilches, A., Vilarrasa, N., Espejo, C., & Montalban, X. (2009) · Clinical Immunology · doi:10.1016/j.clim.2008.12.004 · Cited by 34
Intrathecal chitotriosidase and the outcome of multiple sclerosis
Sotgiu, S., Barone, R., Arru, G., Fois, M. L., Pugliatti, M., Sanna, A., Rosati, G., & Musumeci, S. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070614 · Cited by 33
Tsunoda, I., Kuang, L.-Q., Igenge, I. Z. M., & Fujinami, R. S. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.11.007 · Cited by 28
Buchanan, R. J., Minden, S. L., Chakravorty, B. J., Hatcher, W., Tyry, T., & Vollmer, T. (2010) · Disability and Health Journal · doi:10.1016/j.dhjo.2009.09.003 · Cited by 27
De Masi, R., Vergara, D., Pasca, S., Acierno, R., Greco, M., Spagnolo, L., Blasi, E., Sanapo, F., Trianni, G., & Maffia, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.03.002 · Cited by 26
“Patients were classified as RR according to standard disease course criteria (Lublin and Reingold, 1996) and treated with interferon β-1a at 30 µg I.M. weekly according to international guidelines (Jacobs et al., 1996).”
MethodIncreased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis
Verbeek, M. M., Notting, E. A., Faas, B., Claessens-Linskens, R., & Jongen, P. J. H. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01242.x · Cited by 26
The initial course of daily functioning in multiple sclerosis: a three-year follow-up study
de Groot, V, Beckerman, H., Lankhorst, G. J., Polman, C. H., & Bouter, L. M. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1238oa · Cited by 23
Future‐directed thinking and depression in relapsing‐remitting multiple sclerosis
Moore, A. C., MacLeod, A. K., Barnes, D., & Langdon, D. W. (2006) · British Journal of Health Psychology · doi:10.1348/135910705x85781 · Cited by 20
Anal sphincter dysfunction in multiple sclerosis: an observation manometric study
Marola, S., Ferrarese, A., Gibin, E., Capobianco, M., Bertolotto, A., Enrico, S., Solej, M., Martino, V., Destefano, I., & Nano, M. (2016) · Open Medicine · doi:10.1515/med-2016-0088 · Cited by 18
Rühling, S., Kramer, F., Schmutz, S., Amor, S., Jiangshan, Z., Schmitz, C., Kipp, M., & Hochstrasser, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1353-9 · Cited by 18
Brieva, L., Calles, C., Landete, L., & Oreja-Guevara, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543649 · Cited by 16
Muñoz San José, A., Oreja-Guevara, C., Cebolla Lorenzo, S., Carrillo Notario, L., Rodríguez Vega, B., & Bayón Pérez, C. (2016) · Neurología · doi:10.1016/j.nrl.2015.07.014 · Cited by 14
The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis
Bichuetti, D. B., Falcão, A. B., Boulos, F. D. C., Morais, M. M. D., Lotti, C. B. D. C., Fragomeni, M. D. O., Campos, M. F., Souza, N. A. D., & Oliveira, E. M. L. (2015) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20150004 · Cited by 12
Chauhan, P., Kakkar, A. K., Singh, H., & Gautam, C. S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1838276 · Cited by 12
An Overview of Multiple Sclerosis In Vitro Models
Czpakowska, J., Kałuża, M., Szpakowski, P., & Głąbiński, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147759 · Cited by 7
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis*
- Venue
- Neurology
- Published
- 1996-04
- Volume
- 46
- Issue
- 4
- Pages
- 907-911
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2087589796
- Cited by
- 3,686
- References
- 12
- FWCI
- 45.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.